Gefitinib (ZD1839): Therapy in selected patients with non-small cell lung cancer (NSCLC)?

Lung Cancer

Volumn 61, Issue 1, 2008, Pages 73-81

  Dongiovanni, Diego ^a   Daniele, Lorenzo ^b   Barone, Carla ^a   Dongiovanni, Vincenzo ^a   Fissore, Camilla ^a   Sapino, Anna ^b   Macrì, Luigia ^b   Bussolati, Giovanni ^b   Buffoni, Lucio ^a   Gaspari, Fabio ^a   Grillo, Raffaella ^a   Birocco, Nadia ^a   Addeo, Alfredo ^a   Ciuffreda, Libero ^a   Schena, Marina ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

EGFR mutation; FISH CISH; Gefitinib; NSCLC

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB;

ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE NUMBER; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SKIN TOXICITY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 45649085198     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.12.007     Document Type: Article

References (46)

1. Verdecchia A. Survival in adult patients, 1978-1989 ITACARE working group. Tumori 83 (1997) 39-425
2. Park K. Second-line chemotherapy for advanced non-small cell lung cancer: past, present, and hope for the future. Cancer Res Treat 35 (2003) 279-280
3. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl J Med 346 (2002) 92-98
4. Kelly K., Crowley J., Bunn Jr. P.A., Presant C.A., Grevstad P.K., Moinpour C.M., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a southwest Oncology group trial. J Clin Oncol 19 (2001) 3210-3218
5. Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol 18 (2000) 2354-2362
6. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 (2000) 2095-2103
7. Cohen M.H., Johnson J.R., Wang Y.C., Sridhara R., and Pazdur R. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 10 (2005) 363-368
8. Massarelli E., Andre F., Liu D.D., Lee J.J., Wolf M., Fandi A., et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 39 (2003) 55-61
9. Franklin W.A., Veve R., Hirsch F.R., Helfrich B.A., and Bunn Jr. P.A. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 29 (2002) 3-14
10. Ciardiello F. An update of new targets for cancer treatment: receptor-mediated signals. Ann Oncol 22 (2003) 674 (Abstr 2709)
11. Ciardiello F., De Vita F., Orditura M., and Tortora G. The role of EGFR inhibitors in nonsmall cell lung cancer. Curr Opin Oncol 16 (2004) 130-135
12. Herbst R.S., Maddox A.M., Rothenberg M.L., Small E.J., Rubin E.H., Baselga J., et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 20 (2002) 3815-3825
13. Baselga J., Rischin D., Ranson M., Calvert H., Raymond E., Kieback D.G., et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20 (2002) 4292-4302
14. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 21 (2003) 2237-2246
15. Kris M.G., Natale R.B., Herbst R.S., Lynch Jr. T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA 290 (2003) 2149-2158
16. Cohen M.H., Williams G.A., Sridhara R., Chen G., McGuinn Jr. W.D., Morse D., et al. United States food and drug administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 10 (2004) 1212-1218
17. Shepherd F.A., Pereira J.R., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. New Engl J Med 353 2 (2005) 123-132
18. Miller V.A., Kris M.G., Shah N., Patel J., Azzoli C., Gomez J., et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib (IressaTM ZD1839) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 22 (2004) 1103-1109
19. Shah N.T., Kris M.G., Pao W., Tyson L.B., Pizzo B.M., Heinemann M.H., et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 23 (2005) 165-174
20. Bailey L., Kris M., Wolf M., Kay A., Averbuch S., Askaa J., et al. Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib (Iressa ZD1839) monotherapy for pretreated advanced non-small cell lung cancer: IDEAL 1 and 2. Proc AACR 44 (2003) 1362 (LB-170)
21. Cappuzzo F., Magrini E., Ceresoli G.L., Bartolini S., Rossi E., Ludovini V., et al. Akt phosphorilation and gefitinib efficacy in patiets with advanced non-small-cell lung cancer. J Natl Cancer Inst 96 15 (2004) 1117-1119
22. Han S.W., Hwang P.G., Chung D.H., Kim D.W., Im S.A., Kim Y.T., et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer 113 (2005) 109-115
23. Meert A.P., Martin B., Verdebout J.M., Noël S., Ninane V., Sculier J.P., et al. Is there a relationship between c-erbB1 and c-erbB2 amplification and protein overexpression in NSCLC?. Lung Cancer 47 (2005) 325-336
24. Miller V.A., Shah N., Kris M., Patel J., Venkatraman E., BenPorat L., et al. Clinical pathologic and molecular characteristics of NSCLC patients sensitive to gefitinib. Lung Cancer (2003) 41S71 (Abst O241)
25. Cappuzzo F., Gregorc V., Rossi E., Cancellieri A., Magrini E., Paties C.T., et al. Gefitinib in pretreated non-small-cell ling cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 21 (2003) 2658-2663
26. Cappuzzo F., Varella-Garcia M., Shigematsu H., Domenichini I., Bartolini S., Ceresoli G.L., et al. Increased HER-2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor positive non-small-cell lung cancer patients. J Clin Oncol 23 (2005) 5007-5018
27. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl J Med 350 (2004) 2129-2139
28. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
29. Hirsch F.R., Varella-Garcia M., Bunn Jr. P.A., Di Maria M.V., Veve R., Bremmes R.M., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21 (2003) 3798-3807
30. Zhao X., Weir B.A., LaFramboise T., Lin M., Beroukhim R., Garraway L., et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 65 (2005) 5561-5570
31. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitività in non-small-cell lung cancer. J Natl Cancer Inst 97 (2005) 643-655
32. Takano T., Ohe Y., Sakamoto H., Tsuta K., Matsuno Y., Tateishi U., et al. Epidermal growth factor receptor gene mutations and increased copy number predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23 (2005) 6829-6837
33. Jänne P.A., Gurubhagavatula S., Yeap B.Y., Lucca J., Ostler P., Skarin A.T., et al. Outcomes of patients with advanced non-small call lung cancer treated with gefitinib (ZD1839, Iressa) on an expanded access study. Lung Cancer 44 (2004) 221-230
34. Argiris A., and Mittal N. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. Lung Cancer 43 (2004) 317-322
35. Santoro A., Cavina R., Latteri F., Zucali P.A., Ginanni V., Campagnoli E., et al. Activity of a specific inhibitor, gefitinib (IressaTM, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer. Ann Oncol 15 (2004) 33-37
36. Daniele L., Macri L., Schena M., Dongiovanni D., Bonello L., Armando E., et al. Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens. Mol Cancer Ther 6 4 (2007) 1223-1229
37. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
38. Giaccone G. Epidermal growth factor receptors inhibitors in the treatment of non-small cell lung cancer. J Clin Oncol 23 (2005) 3235-3242
39. Giaccone G. The role of gefitinib in lung cancer treatment. Clin Cancer Res 10 (2004) 4233S-4237S
40. Marchetti A., Martella C., Felicioni L., Barassi F., Salvatore S., Chella A., et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23 (2005) 857-865
41. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23 11 (2005) 2513-2520
42. Jackman D.M., Yeap B.Y., Sequist L.V., Lindeman N., Holmes A.J., Joshi V.A., et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 12 July 13 (2006) 3908-3914
43. Riely G.J., Pao W., Pham D., Li A.R., Rizvi N., Venkatraman E.S., et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 1 12 (2006) pp. 839-834
44. Nomura M., Shigematsu H., Li L., Suzuki M., Takahashi T., Estess P., et al. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med 4 4 (2007) e125
45. Moasser M.M., Basso A., Avebuch S.D., and Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signalling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61 (2001) 7184-7188
46. Dziadziuszko R., Witta S.E., Cappuzzo F., Park S., Tanaka K., Danenberg P.V., et al. Epidermal growth factor receptor messenger RNA expression, gene dosage and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res 12 (2006) 3078-3084